Generic Companies with Tentative Approvals for: Mylan Pharms Inc

✉ Email this page to a colleague

Mylan Pharms Inc Generic Filers with Tentative Approvals

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Try for Free
Applicant	Generic Name	NDA	Strength	Dosage Form
Mylan Pharms Inc	sertraline hydrochloride	076540	EQ 25MG BASE	TABLET;ORAL
Mylan Pharms Inc	zolpidem tartrate	078016	10MG	TABLET;ORAL
Mylan Pharms Inc	darunavir and ritonavir	209847	400MG/50MG	TABLET; ORAL
Mylan Pharms Inc	fluconazole	076042	200MG	TABLET;ORAL
Mylan Pharms Inc	milnacipran hydrochloride	205367	100MG	TABLET;ORAL
Mylan Pharms Inc	sugammadex	213915	200MG/2ML	INJECTABLE;INJECTION
Mylan Pharms Inc	sitagliptin phosphate	202473	EQ 50MG BASE	TABLET; ORAL
>Applicant	>Generic Name	>NDA	>Strength	>Dosage Form

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.